Researchers corrected a hidden DNA mutation in human cells linked to propionic acidemia. The experiment restored production of the affected protein and could help improve diagnosis and future personalized treatments.
A team from the Centro de Biología Molecular Severo Ochoa corrected a hidden DNA mutation in human cells linked to propionic acidemia. The experiment restored normal production of the affected protein. It also addresses a problem with diagnosis because standard genetic tests can miss this type of change.
The work was carried out by the joint centre of the CSIC and the Universidad Autónoma de Madrid under the leadership of Lourdes Desviat. According to the CSIC, the researchers used precision gene-editing techniques to repair a wrong genetic instruction hidden outside the gene itself.
The alteration affects the PCCA gene, and reports identify CRISPR-Cas12a as the tool used to disable the hidden error signal in the genetic instructions.
These changes are known as deep or cryptic mutations. They do not directly alter the part of a gene that carries the coding sequence. They can still disrupt the process that turns genetic information into proteins. When that process fails, cells may not produce an essential enzyme even when the most visible parts of the gene appear intact.
That hidden process is what makes the experiment important.
Propionic acidemia is a rare, potentially life-threatening metabolic disorder present from birth. It can appear during the first days or months of life and may trigger severe metabolic crises in childhood. The disease can also cause neurological, cardiac or pancreatic complications during adolescence and adulthood.
In the reported mechanism, the concealed signal inserts an extra fragment into the RNA, interfering with the normal assembly of the enzyme. Disabling that signal allowed the edited human cells to produce the required protein fragment again.
There is currently no cure for the condition. The new work is not a treatment for patients. It shows, in an experimental cellular model, that a permanent correction may be possible at the level of the DNA defect.
The study is part of a wider effort to find biological mechanisms that standard testing can miss. A related example appears in the report on active meprin-β found in Alzheimer's brain samples, although the disease and the mechanism are different.
For people with propionic acidemia, the study's immediate value is both diagnostic and therapeutic. An undetected mutation can make it harder to explain why the body fails to produce the required protein. Precision editing offers a way to target the genetic error itself instead of only managing the effects of the metabolic disorder.
The researchers describe the findings as a proof of concept for future therapies. The method could also be studied for other diseases caused by similar defects in parts of DNA that standard analysis often misses. Servimedia and other reports describe propionic acidemia as a rare disorder that can be life-threatening and affect several organ systems. That adds to the case for better molecular diagnosis.
The evidence is still limited to human cells in an experimental model. It does not establish a treatment ready for clinical use. The CSIC and UAM team has shown that gene editing can reach mutations beyond the most visible parts of a gene and restore protein production. This makes the work a credible starting point for personalized medicine in rare inherited diseases, not a completed cure.
